Injective (INJ) is currently trading at $2.80, reflecting a 24-hour decline of 3.46%. The daily range has been narrow, with a high of $2.91 and a low of $2.79, indicating subdued volatility in the short term.

The volume over the past 24 hours stands at approximately $30 million, contributing to a volume-to-market cap ratio of 10.74%. This suggests a relatively healthy trading environment, although the declining price trend might be discouraging for new buyers.

Analyzing moving averages, the 8, 13, and 21 SMAs are showing negative momentum, with the 55 SMA also indicating a downward trend. The 144 SMA at $2.97 further emphasizes a bearish outlook, suggesting that the price is below longer-term average levels, which could lead to additional selling pressure.

The 1-hour RSI is at 29, indicating oversold conditions, while the 7-day RSI at 43 suggests that the asset is approaching neutral territory but still trending downwards. The 7-day, 14-day, and 30-day price changes of -5.82%, -8.46%, and -10.55%, respectively, confirm a persistent bearish trend over recent weeks.

Given the current price action, the proximity to the all-time high of $52.62 achieved in March 2024 highlights the significant price retracement that INJ has experienced. This steep decline raises concerns about market sentiment and investor confidence, particularly as the asset struggles to reclaim higher price levels.

In conclusion, the combination of negative momentum indicators, declining RSI values, and the broader bearish trend leads to a Sell rating for Injective (INJ). Investors should consider liquidating their positions or avoiding new entries until clearer signs of a trend reversal emerge.